Contact Us
Your location:
Home
 / Contact Us
/
/

[Column] The era of generic drugs is coming, and patent protection will be weakened in China?

  • Categories:Carrers
  • Time of issue:2018-07-05

[Column] The era of generic drugs is coming, and patent protection will be weakened in China?

  • Categories:Carrers
  • Time of issue:2018-07-05

 

On May 8, 2015, the State Council officially issued "Made in China 2025", adhered to the basic policy of "innovation-driven, quality-first, green development, structural optimization, and talent-oriented", and adhered to "market-led, government-led, based on current, Focus on the long-term, the overall principle of overall promotion, key breakthroughs, independent development, and open cooperation. Biomedicine and high-performance medical devices have become one of the top ten areas for development.
 
On July 22, 2015, since the clinical self-examination, China entered the reform zone in the pharmaceutical field. With the introduction of the consistency evaluation policy, pharmaceutical R&D and production reform entered the deep water area.
 
On April 3, 2018, the General Office of the State Council issued the "Opinions on Reforming and Improving the Policy of Supply and Use of Generic Drugs" (hereinafter referred to as "Opinions"). The release of this article represents China's willingness to change from a generic drug country to a generic drug power. The "Opinions" mainly elaborated on the thre